LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-2.99%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$260M
AUM Growth
+$260M
(-26%)
Cap. Flow
-$39.8M
Cap. Flow
% of AUM
-15.27%
Top 10 Holdings %
Top 10 Hldgs %
50.97%
Holding
59
New
21
Increased
10
Reduced
8
Closed
19
Top Buys
| 1 |
AbbVie
ABBV
|
$20.2M |
| 2 |
Moderna
MRNA
|
$13.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$10.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$9.5M |
| 5 |
Passage Bio
PASG
|
$8.96M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$20.6M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$18M |
| 3 |
BLUE
bluebird bio
BLUE
|
$17.9M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$15.9M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 93.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Amicus Therapeutics
FOLD
$2.34B
| $4.13M | 1.57% | +446,882 | New | +$4.13M |
|
|
TRIL
27
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.02M | 1.53% | +995,600 | New | +$4.02M |
|
|
LSACU
28
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $4M | 1.52% | +400,000 | New | +$4M |
|
|
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
| $3.76M | 1.43% | 152,144 -134,880 | -47% | -$3.34M |
|
|
IMMU
30
DELISTED
Immunomedics Inc
IMMU
| $3.73M | 1.42% | +276,635 | New | +$3.73M |
|
|
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.57M | 1.36% | 46,399 -207,261 | -82% | -$15.9M |
|
32
Black Diamond Therapeutics
BDTX
$157M
| $2.77M | 1.05% | +123,465 | New | +$2.77M |
|
33
Cartesian Therapeutics
RNAC
$261M
| $2.68M | 1.02% | +1,111,867 | New | +$2.68M |
|
34
TG Therapeutics
TGTX
$4.65B
| $2.46M | 0.94% | +249,844 | New | +$2.46M |
|
35
Cytokinetics
CYTK
$4.23B
| $2.28M | 0.87% | +193,129 | New | +$2.28M |
|
|
SAGE
36
DELISTED
Sage Therapeutics
SAGE
| $2M | 0.76% | 69,591 -120,559 | -63% | -$3.46M |
|
37
Minerva Neurosciences
NERV
$16.5M
| $1.87M | 0.71% | 309,745 +81,910 | +36% | +$493K |
|
38
Savara
SVRA
$567M
| $1.17M | 0.45% | 613,999 | – | – |
|
39
Revolution Medicines
RVMD
$7.1B
| $1.16M | 0.44% | +53,034 | New | +$1.16M |
|
40
Rocket Pharmaceuticals
RCKT
$354M
| $221K | 0.08% | 15,809 -207,528 | -93% | -$2.9M |
|
|
AMRN
41
Amarin Corp
AMRN
$311M
| – | – | -962,553 | Closed | -$20.6M |
|
|
42
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | -587,108 | Closed | -$18M |
|
43
Ardelyx
ARDX
$1.53B
| – | – | -212,449 | Closed | -$1.59M |
|
44
Assembly Biosciences
ASMB
$190M
| – | – | -188,000 | Closed | -$3.85M |
|
45
Axsome Therapeutics
AXSM
$6.05B
| – | – | -124,937 | Closed | -$12.9M |
|
|
BLUE
46
DELISTED
bluebird bio
BLUE
| – | – | -204,420 | Closed | -$17.9M |
|
47
Kezar Life Sciences
KZR
$28.9M
| – | – | -122,931 | Closed | -$493K |
|
48
Madrigal Pharmaceuticals
MDGL
$9.76B
| – | – | -27,279 | Closed | -$2.49M |
|
49
MEI Pharma
MEIP
$160M
| – | – | -1,145,528 | Closed | -$2.84M |
|
50
Neurogene
NGNE
$264M
| – | – | -40,529 | Closed | -$499K |
|